Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Cytokeratin 8/KRT8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KRT8 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for immunization and ELISA standards. |
View KRT8 Products |
| Gene Delivery | KRT8 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View KRT8 Products |
| Benchmark Ab | Anti-KRT8 (Sequence of clinical/diagnostic clones) Recombinant positive control for assay benchmarking. |
View KRT8 Products |
| Validator | KRT8 siRNA Set For target knockdown verification and specificity assays. |
View KRT8 Products |
| Related Target A | KRT18 Primary heterodimerization partner of KRT8; critical for intermediate filament formation and joint biomarker assays. |
View KRT18 Products |
| Related Target B | KRT19 Co-expressed epithelial marker; essential for cross-reactivity screening and diagnostic panel development. |
View KRT19 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating KRT8 from other keratins (KRT18/KRT19) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Evaluating surface vs. intracellular binding | Lentivirus-driven stable cell lines available for flow cytometry and live-cell binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live Cytokeratin 8/KRT8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical utility of Cytokeratin 8 (KRT8) is expanding rapidly. Traditionally utilized as a gold-standard diagnostic immunohistochemistry (IHC) marker for epithelial tumors, KRT8 is transitioning into a therapeutic target. The race for KRT8 therapeutics is intensifying, with major players shifting focus from traditional diagnostic mAbs to targeted intracellular delivery and cell-surface KRT8-directed therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting KRT8-mediated drug resistance pathways and its role in epithelial-mesenchymal transition (EMT) in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostics (IHC/ELISA) | Roche/Ventana, Agilent/Dako | Carcinomas, Adenocarcinomas | High-specificity screening (Need purified KRT8 and KRT18/19 for cross-reactivity panels) |
| Therapeutic mAbs / ADCs | Preclinical Biotechs, Academic Institutions | Triple-Negative Breast Cancer, Lung Cancer | Surface antigen conformation validation (Need Lentivirus for stable cell line generation) |
| Small Molecule / siRNA | Oncology-focused Biotechs | Drug-resistant Epithelial Tumors | Target knockdown validation (Need KRT8 siRNA sets and mutant recombinant proteins) |